Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799332 | 1.00 | RAB9A (0.56) | RAB9AEPHX2EPHX1SMN1; SMN2PDK1 | |
| SCHEMBL6799335 | 1.00 | RAB9A (0.56) | RAB9AEPHX2EPHX1SMN1; SMN2PDK1 | |
| SCHEMBL6804807 | 0.82 | MEN1 (0.52) | RAB9ASMN1; SMN2PDK1ALDH1A1KMT2A | |
| SCHEMBL6804810 | 0.82 | MEN1 (0.52) | RAB9ASMN1; SMN2PDK1ALDH1A1KMT2A | |
| SCHEMBL15263046 | 0.80 | EPHX1 (0.83) | RAB9AEPHX2EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10825858 | 0.80 | EPHX1 (0.83) | RAB9AEPHX2EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31054297 | 0.79 | RAB9A (0.71) | RAB9AEPHX2EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11316579 | 0.79 | RAB9A (0.60) | RAB9AEPHX2EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31280763 | 0.79 | RAB9A (0.60) | RAB9AEPHX2EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6806375 | 0.79 | TYR (0.58) | RAB9ASMN1; SMN2FAAHKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | claimed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | claimed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | RAB9A 2365/4885EPHX2 2360/4885EPHX1 1031/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | RAB9A 2365/4885EPHX2 2360/4885EPHX1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.